Literature DB >> 30107907

Varying Effects of Body Mass Index and Mortality in Different Risk Groups.

Pablo Lamelas1, J D Schwalm2, Darryl Leong2, Sanjit Jolly2, Shamir Mehta2, Shrikant Bangdiwala2, Salim Yusuf2.   

Abstract

It is unclear why high body mass index (BMI) is associated with a lower risk of death in patients with cardiovascular disease (CVD). We hypothesized that the impact of higher BMI varies by the patient's baseline risk of death. We analyzed data from 14 prospective studies conducted by us in 50 countries of 170,470 patients: 22.8% without CVD, 29.4% with stable CVD and 47.8% with acute coronary syndromes (ACS). Compared with overweight (BMI 25 to 29.9 kg/m2), normal weight (BMI 20 to 24.9 kg/m2), and underweight (BMI < 20 kg/m2) were associated with higher mortality in all cohorts. Compared with overweight, the risk of death among those with obesity (BMI ≥ 30 kg/m2) varied depending on the population studied: HR (95% confidence interval) in those without CVD, with stable CVD, and with ACS were 1.20 (1.01 to 1.45; p = 0.04), 1.08 (1.02 to 1.15; p = 0.01), and 1.01 (0.93 to 1.10; p = 0.72), respectively. The BMI associated with lowest mortality increased as cohort risk increased (no-CVD 27.2 kg/m2, stable CVD 28.1 kg/m2, and ACS 30.9 kg/m2; p <0.001). Within each cohort, the optimal BMI value was higher in the high-risk subgroup. In the ACS cohort, low-risk patients had an optimal BMI value of 29.1 kg/m2 while in the high-risk group higher BMI was associated with lower risk of death (interaction-p <0.001). In conclusion, between and within cohorts of people without CVD, stable CVD, and ACS, higher BMI was associated with lower risk of death in higher risk groups. The benefits of increased body fat (i.e., increased caloric reserve) may counteract the hazards in high-risk groups, suggesting an alternative explanation of the obesity paradox.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30107907     DOI: 10.1016/j.amjcard.2018.06.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Mortality risk in patients with underweight or obesity with peripheral artery disease: a meta-analysis including 5,735,578 individuals.

Authors:  Donna Shu-Han Lin; Hao-Yun Lo; An-Li Yu; Jen-Kuang Lee; Kuo-Liong Chien
Journal:  Int J Obes (Lond)       Date:  2022-05-16       Impact factor: 5.551

2.  Tesamorelin improves fat quality independent of changes in fat quantity.

Authors:  Jordan E Lake; Kristen La; Kristine M Erlandson; Stefan Adrian; Gayane Yenokyan; Ann Scherzinger; Michael P Dubé; Takara Stanley; Steven Grinspoon; Julian Falutz; Jean-Claude Mamputu; Christian Marsolais; Grace A McComsey; Todd T Brown
Journal:  AIDS       Date:  2021-07-15       Impact factor: 4.632

3.  Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial.

Authors:  Wolfram Doehner; Hertzel C Gerstein; Janina Ried; Hyejung Jung; Christian Asbrand; Sibylle Hess; Stefan D Anker
Journal:  Eur Heart J       Date:  2020-07-21       Impact factor: 29.983

4.  Synergistic Impact of Body Mass Index and Cognitive Function on All-Cause Mortality in Older Adults: A Nationwide Longitudinal Study.

Authors:  Ke Han; Wangping Jia; Shengshu Wang; Wenzhe Cao; Yang Song; Jianwei Wang; Miao Liu; Shanshan Yang; Yao He
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-29       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.